LLY

Eli Lilly and Co

Add to Watchlist

Advanced Chart

812.690

+7.26(0.901%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

815.190

Open

809.000

VWAP

810.26

Vol

2.98M

Mkt Cap

770.22B

Low

802.370

Amount

2.41B

EV/EBITDA(TTM)

37.06

Total Shares

950.41M

798.71B

EV/OCF(TTM)

85.72

P/S(TTM)

14.85

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity, and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule, FXR314.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

17.11B

+26.47%

6.856

+28.87%

15.43B

+34.89%

6.168

+422.69%

14.55B

+28.73%

5.548

+41.53%

Estimates Revision

The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 0.67% over the past three months. During the same period, the stock price has changed by -7.36%.

Revenue Estimates for FY2025

Revise Upward

+0.67%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.55%

In Past 3 Month

Stock Price

Go Down

-7.36%

In Past 3 Month

19 Analyst Rating

23.00% Upside

Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 999.57 USD with a low forecast of 700.00 USD and a high forecast of 1190 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

2 Hold

1 Sell

Strong Buy

23.00% Upside

Current: 812.690

Low

700.00

Averages

999.57

High

1190

23.00% Upside

Current: 812.690

Low

700.00

Averages

999.57

High

1190

Morgan Stanley

Overweight

maintain

2025-07-10

Reason

Morgan Stanley

Price Target

2025-07-10

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Eli Lilly to $1,135 from $1,133 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.

BMO Capital

Outperform -> Market Perform

downgrade

$13.50

2025-06-26

Reason

BMO Capital

Price Target

$13.50

2025-06-26

downgrade

Outperform -> Market Perform

Reason

Needham

Buy

Hold

downgrade

$65

2025-06-23

Reason

Needham

Price Target

$65

2025-06-23

downgrade

Buy

Hold

Reason

Jefferies

Buy -> Hold

downgrade

$28 -> $11

2025-06-19

Reason

Jefferies

Price Target

$28 -> $11

2025-06-19

downgrade

Buy -> Hold

Reason

Erste Group

Buy

Hold

downgrade

2025-06-05

Reason

Erste Group

Price Target

2025-06-05

downgrade

Buy

Hold

Reason

Erste Group downgraded Eli Lilly to Hold from Buy. The company lowered its earnings forecast for 2025, says the firm, which expects the shares to trend sideways in the medium term.

Cantor Fitzgerald

Carter Gould

Buy

Initiates

$975

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

$975

2025-04-22

Initiates

Buy

Reason

Cantor Fitzgerald initiated coverage of Eli Lilly with an Overweight rating and $975 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Eli Lilly and Co (LLY.N) is 32.15, compared to its 5-year average forward P/E of 39.49. For a more detailed relative valuation and DCF analysis to assess Eli Lilly and Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

39.49

Current PE

32.15

Overvalued PE

52.20

Undervalued PE

26.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

29.53

Current EV/EBITDA

24.10

Overvalued EV/EBITDA

37.91

Undervalued EV/EBITDA

21.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

10.59

Current PS

11.43

Overvalued PS

13.85

Undervalued PS

7.32

Financials

Annual

Quarterly

FY2025Q1

YoY :

+45.17%

12.73B

Total Revenue

FY2025Q1

YoY :

+102.40%

5.30B

Operating Profit

FY2025Q1

YoY :

+23.02%

2.76B

Net Income after Tax

FY2025Q1

YoY :

+23.39%

3.06

EPS - Diluted

FY2025Q1

YoY :

-2024.16%

-1.60B

Free Cash Flow

FY2025Q1

YoY :

+2.00%

82.53

Gross Profit Margin - %

FY2025Q1

YoY :

-76.11%

-2.59

FCF Margin - %

FY2025Q1

YoY :

-15.25%

21.68

Net Margin - %

FY2025Q1

YoY :

+32.56%

25.24

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 31365.12% over the last month.

Sold

0-3

Months

226.1M

USD

3-6

Months

2.4B

USD

6-9

Months

0.0

USD

0-12

Months

47.8M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

9.3K

Volume

3-6

Months

922.2K

Volume

6-9

Months

182.5K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.2M

Volume

Months

6-9

2.4M

Volume

Months

0-12

1.5K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

231.5K

USD

3-6

Months

228.0K

USD

6-9

Months

185.5K

USD

0-12

Months

8.0K

USD

Bought

0-3

40.0K

USD

Months

3-6

256.0K

USD

Months

6-9

91.0K

USD

Months

0-12

32.5K

USD

Months

Insider

Insiders areSelling! The selling amount has increased 31365.12% over the last month.

Sold

0-3

Months

226.1M

USD

3-6

Months

2.4B

USD

6-9

Months

0.0

USD

0-12

Months

47.8M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

LLY News & Events

Events Timeline

2025-07-25 (ET)

2025-07-25

08:50:13

Eli Lilly completes acquisition of Verve Therapeutics

2025-07-25

06:30:51

Eli Lilly receives CHMP opinion recommending donanemab for Alzheimer's

2025-07-24 (ET)

2025-07-24

08:09:44

Eli Lilly and Verve Therapeutics announce expiration of Verve tender offer

News

9.5

07-24PRnewswire

PinnedLilly confirms date and conference call for second-quarter 2025 financial results announcement

9.0

07-25TipRanks

PinnedEurope Grants Limited Approval to Eli Lilly’s (LLY) Alzheimer’s Drug

9.0

07-25Newsfilter

PinnedDonanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease

People Also Watch

Berkshire Hathaway Inc

Costco Wholesale Corp

UnitedHealth Group Inc

FAQ

What is Eli Lilly and Co (LLY) stock price today?

The current price of LLY is 812.69 USD — it has increased 0.9 % in the last trading day.

LLY

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

LLY News & Events

Events Timeline

News

People Also Watch

FAQ

What is Eli Lilly and Co (LLY) stock price today?

What is Eli Lilly and Co (LLY)'s business?

What is the price predicton of LLY Stock?

What is Eli Lilly and Co (LLY)'s revenue for the last quarter?

What is Eli Lilly and Co (LLY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Eli Lilly and Co (LLY)'s fundamentals?

How many employees does Eli Lilly and Co (LLY). have?

What is Eli Lilly and Co (LLY) market cap?